{"doi":"10.1016/j.imbio.2011.11.001","title":"Response to “Ipilimumab (Yervoy) and the TGN1412 catastrophe”","abstract":null,"journal":"Immunobiology","year":2012,"id":594009,"datarank":0.41588830833596724,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.0,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":68930,"name":"Margaret K. Callahan","orcid":"0000-0002-9087-0012","position":1,"is_corresponding":false},{"id":230235,"name":"Sumit K. Subudhi","orcid":"0000-0001-5208-7732","position":2,"is_corresponding":false},{"id":90470,"name":"James P. Allison","orcid":"0000-0001-8980-5697","position":3,"is_corresponding":false},{"id":271524,"name":"Michael A. Curran","orcid":"0000-0003-4996-7207","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Response to “Ipilimumab (Yervoy) and the TGN1412 catastrophe”","abstract":null,"is_dataset_classified":null,"base_score":2.772588722239781,"endowment":2.772588722239781,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22459268","pmcid":null,"openalex_id":"https://openalex.org/W2059315875","authors":[],"funders":[],"total_grants":0,"fwci":0.6503,"citation_percentile":0.69319991,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":1},{"year":2014,"count":3},{"year":2015,"count":2},{"year":2018,"count":1},{"year":2019,"count":2},{"year":2020,"count":1},{"year":2024,"count":2},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0171298511002488?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0171298511002488?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.imbio.2011.11.001","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22459268","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","T-cell and B-cell Immunology","Immunotherapy and Immune Responses"],"mesh_terms":["Ipilimumab","Antibodies, Monoclonal","Humans","Immunization, Passive","Melanoma","Skin Neoplasms","CTLA-4 Antigen"],"keywords":["Ipilimumab","CTLA-4","Blockade","Medicine","Pathognomonic","Immunology","Immune checkpoint","Antibody","Adverse effect","Disease","Haploinsufficiency","Blocking antibody","Immune system","Immunotherapy","Internal medicine","T cell","Biology","Phenotype"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Climate action"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T13:10:38.740690Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}